Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML.
Murphy T, Zou J, Daher-Reyes GS, Arruda A, Gupta V, McNamara CJ, Minden MD, Schimmer AD, Sibai H, Yee KWL, Korulla M, Stockley T, Kamel-Reid S, Maze D, Tierens A, Bratman SV, Schuh AC, Chan SM.
Murphy T, et al. Among authors: minden md.
Blood Adv. 2019 Aug 13;3(15):2307-2311. doi: 10.1182/bloodadvances.2019000306.
Blood Adv. 2019.
PMID: 31371380
Free PMC article.